| Safety of Clinical Trial Participants |
Discussion, by world region, of management process for ensuring quality and patient safety
during clinical trials |
HC-BP-210a.1 |
|
| Number of FDA Sponsor Inspections related to clinical trial management and pharmacovigilance
that resulted in: (1) Voluntary Action Indicated (VAI) and (2) Official Action Indicated (OAI)
|
HC-BP-210a.2 |
|
| Total amount of monetary losses as a result of legal proceedings associated with clinical
trials in developing countries |
HC-BP-210a.3 |
- No business in developing countries
|
| Access to Medicines |
Description of actions and initiatives to promote access to healthcare products for priority
diseases and in priority countries as defined by the Access to Medicine Index |
HC-BP-240a.1 |
- No business in priority countries
|
| List of products on the WHO List of Prequalified Medicinal Products as part of its
Prequalification of Medicines Programme (PQP) |
HC-BP-240a.2 |
|
| Afordability & Pricing |
Number of settlements of Abbreviated New Drug Application (ANDA) litigation that involved
payments and/or provisions to delay bringing an authorized generic product to market for a
defined time period |
HC-BP-240b.1 |
|
| Percentage change in: (1) average list price and (2) average net price across U.S. product
portfolio compared to previous year |
HC-BP-240b.2 |
|
| Percentage change in: (1) list price and (2) net price of product with largest increase
compared to previous year |
HC-BP-240b.3 |
- Product: LUTEUM (1)NHI Price: 541.90 (2)Net Price: Not disclosed
|
| Drug Safety |
List of products listed in the Food and Drug Administration’s (FDA) MedWatch Safety Alerts for
Human Medical Products database |
HC-BP-250a.1 |
|
| Number of fatalities associated with products as reported in the FDA Adverse Event Reporting
System |
HC-BP-250a.2 |
|
| Number of recalls issued, total units recalled |
HC-BP-250a.3 |
|
| Total amount of product accepted for take-back, reuse, or disposal |
HC-BP-250a.4 |
|
| Number of FDA enforcement actions taken in response to violations of current Good
Manufacturing Practices (cGMP), by type |
HC-BP-250a.5 |
|
| Counterfeit Drugs |
Description of methods and technologies used to maintain trace ability of products throughout
the supply chain and prevent counterfeiting |
HC-BP-260a.1 |
|
| Discussion of process for alerting customers and business partners of potential or known risks
associated with counterfeit products |
HC-BP-260a.2 |
|
| Number of actions that led to raids, seizure, arrests, and/or filing of criminal charges
related to counterfeit products |
HC-BP-260a.3 |
|
| Ethical Marketing |
Total amount of monetary losses as a result of legal proceedings associated with false
marketing claims |
HC-BP-270a.1 |
|
| Description of code of ethics governing promotion of off-label use of products |
HC-BP-270a.2 |
|
| Employee Recruitment, Development & Retention |
Discussion of talent recruitment and retention efforts for scientists and research and
development personnel |
HC-BP-330a.1 |
|
| (1) Voluntary and (2) involuntary turn over rate for: (a) executives/seniormanagers, (b)
mid-level managers, (c) professionals, and (d) all others |
HC-BP-330a.2 |
|
| SupplyChain Management |
Percentage of (1) entity's facilities and (2) Tier 1 suppliers' facilities participating in
the Rx-360 International Pharmaceutical Supply Chain Consortium audit program or equivalent
third-party audit programs for integrity of supply chain and ingredients |
HC-BP-430a.1 |
|
| Business Ethics |
Total amount of monetary losses as a result of legal proceedings associated with corruption
and bribery |
HC-BP-510a.1 |
|
| Description of code of ethics governing interactions with health care professionals |
HC-BP-510a.2 |
|